These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2897375)

  • 21. Interaction of talinolol and sulfasalazine in the human gastrointestinal tract.
    Terhaag B; Palm U; Sahre H; Richter K; Oertel R
    Eur J Clin Pharmacol; 1992; 42(4):461-2. PubMed ID: 1355428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gas chromatographic-mass spectrometric assay for the ultra-short-acting beta-blocker esmolol.
    Sum CY; Yacobi A
    J Pharm Sci; 1984 Aug; 73(8):1177-9. PubMed ID: 6149299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of esmolol and ASL-8123 in renal failure.
    Flaherty JF; Wong B; La Follette G; Warnock DG; Hulse JD; Gambertoglio JG
    Clin Pharmacol Ther; 1989 Mar; 45(3):321-7. PubMed ID: 2563962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Determination of talinolol in human plasma by high-performance liquid chromatography (author's transl)].
    Pötter H; Hülm M; Richter K
    J Chromatogr; 1982 May; 241(1):189-92. PubMed ID: 6125524
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetics of flestolol in man: preliminary data.
    Achari R; Hulse JD; Drissel D; Matier WL
    Br J Clin Pharmacol; 1985 Dec; 20(6):691-4. PubMed ID: 2868745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of xamoterol in human plasma by high-performance liquid chromatography with electrochemical detection.
    Davis PC
    J Chromatogr; 1987 Jun; 417(1):233-5. PubMed ID: 2887582
    [No Abstract]   [Full Text] [Related]  

  • 27. Determination of betaxolol in plasma by high-performance liquid chromatography with fluorescence detection.
    Canal M; Flouvat B
    J Chromatogr; 1985 Jul; 342(1):212-5. PubMed ID: 2864353
    [No Abstract]   [Full Text] [Related]  

  • 28. Determination of carboxybupranolol, the major metabolite of bupranolol, in human plasma by high-performance liquid chromatography.
    Walmsley LM; Brodie RR; Chasseaud LF
    J Chromatogr; 1984 Nov; 311(1):227-33. PubMed ID: 6151568
    [No Abstract]   [Full Text] [Related]  

  • 29. Bioavailability of indenolol by nasal and intravenous routes.
    Babhair SA; Tariq M
    Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):137-40. PubMed ID: 2895489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115). 1. Blood levels in dogs].
    Femmer K; Klemm W; Nürnberger H
    Pharmazie; 1975 Oct; 30(10):673-5. PubMed ID: 694
    [No Abstract]   [Full Text] [Related]  

  • 31. Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects.
    Ludden TM; Boyle DA; Gieseker D; Kennedy GT; Crawford MH; Ludden LK; Clementi WA
    J Pharm Sci; 1988 Sep; 77(9):779-83. PubMed ID: 2906367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-performance liquid chromatographic assay for determination of a new beta-blocking agent FM 24.
    Lefebvre MA; Julian B; Fourtillan JB
    J Chromatogr; 1982 Jun; 230(1):199-202. PubMed ID: 6125522
    [No Abstract]   [Full Text] [Related]  

  • 33. Electrophysiology of esmolol.
    Greenspan AM; Spielman SR; Horowitz LN; Senior S; Steck J; Laddu A
    Am J Cardiol; 1985 Oct; 56(11):19F-26F. PubMed ID: 2864844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of esmolol and metabolite enantiomers within human plasma using chiral column chromatography.
    Fang L; Bykowski-Jurkiewicz C; Sarver JG; Erhardt PW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Sep; 878(26):2449-52. PubMed ID: 20708984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
    Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of temperature on in vitro metabolism of esmolol.
    Melendez JA; Stone JG; Delphin E; Quon CY
    J Cardiothorac Anesth; 1990 Dec; 4(6):704-6. PubMed ID: 1983408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simple method for routine determination of betaxolol in blood and urine by automated high-performance liquid chromatography with fluorimetric detection.
    Caqueret H; Bianchetti G
    J Chromatogr; 1984 Nov; 311(1):199-205. PubMed ID: 6151567
    [No Abstract]   [Full Text] [Related]  

  • 38. Species differences in the stereoselective hydrolysis of esmolol by blood esterases.
    Quon CY; Mai K; Patil G; Stampfli HF
    Drug Metab Dispos; 1988; 16(3):425-8. PubMed ID: 2900735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of dodecyl sulfate as an esterase inhibitor before gas-chromatographic determination of labile beta-adrenoceptor blocking drugs.
    Holm G; Kylberg-Hanssen K; Svensson L
    Clin Chem; 1985 Jun; 31(6):868-70. PubMed ID: 2859935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability of esmolol hydrochloride and sodium nitroprusside in intravenous admixtures.
    Karnatz NN; Wong J; Baaske DM; Johnson JH; Speicher ER; Herbranson DE
    Am J Hosp Pharm; 1989 Jan; 46(1):101-4. PubMed ID: 2565685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.